185099-67-6

Basic information

• Product Name: N-Boc-Nortropinone
• Synonyms: BOC-NORTROPINONE;BOC-NTP;8-BOC-8-AZABICYCLO[3.2.1]OCTAN-3-ONE;8-AZABICYCLO[3.2.1]OCTAN-3-ONE, N-BOC PROTECTED;N-BOC-NORTROPINONE;TERT-BUTYL 3-OXO-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE;RARECHEM EM WB 0263;N-(tert-Butoxycarbonyl)nortropinone
• CAS NO: 185099-67-6
• Molecular Formula: C₁₂H₁₉NO₃
• Molecular Weight: 225.28
• EINECS: 1592732-453-0
• Product Categories: pharmacetical;Heterocyclic Compounds;Heterocycle;Various Intermediates;Heterocycles;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;Fused Ring Systems
• Mol File: 185099-67-6.mol

Chemical Properties

• Melting Point: 70-74 °C
• Boiling Point: 325.8 °C at 760 mmHg
• Flash Point: 150.8 °C
• Appearance: off-white solid
• Density: 1.139 g/cm³
• Vapor Pressure: 0.000225mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: Store at 0-5°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -1.65±0.20(Predicted)
• CAS DataBase Reference: N-Boc-Nortropinone(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-Nortropinone(185099-67-6)
• EPA Substance Registry System: N-Boc-Nortropinone(185099-67-6)

Safety Data

• Hazard Codes: Xi
• Statements: 41-36/37/38
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 185099-67-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Boc-Nortropinone is used as an opioid receptor modulator for its ability to interact with and modulate the activity of opioid receptors in the body. This application is particularly relevant in the development of medications aimed at treating pain and addiction, as well as other conditions that may be influenced by the opioid system.
Used in Research and Development:
In addition to its pharmaceutical applications, N-Boc-Nortropinone is also utilized as a research tool in the field of medicinal chemistry. Its role as an opioid receptor modulator makes it a valuable compound for studying the mechanisms of action, binding properties, and potential therapeutic effects of various opioid-related drugs and treatments.

InChI:InChI=1/C12H19NO3/c1-12(2,3)16-11(15)13-8-4-5-9(13)7-10(14)6-8/h8-9H,4-7H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 25602-68-0 3-oxo-8-azabicyclo[3.2.1]octane hydrochloride 
• 28957-72-4 N-benzyltropinone 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 532-24-1 tropinone 
• 34619-03-9 tert-butyldicarbonate 
• 28957-72-4 N-benzylnortropinone 
• 532-24-1 tropinone 
• 5632-84-8 8-azabicyclo[3.2.1]octan-3-one 
• 1185453-81-9 1-(1-(4-methoxyphenyl)pyrrolidin-2-yl)propan-2-one 
• 1159826-74-0 (1R,5S)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]octane-3-carboxylic acid 
• 5632-84-8 nortropinone 
• 542-05-2 acetonedicarboxylic acid 
• 638-37-9 butanedial 

Downstream Products

• 865106-60-1 tert-butyl 3-(2-ethoxy-2-oxoethylidene)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 185099-68-7 tert‐butyl 3‐(trifluoromethanesulfonyloxy)‐8‐azabicyclo[3.2.1]oct‐2‐ene‐8‐carboxylate 
• 617714-57-5 3-(4-Chloro-benzylidene)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 863394-54-1 (1R,3R,5S)-3-(3,4-Dichloro-phenyl)-3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 1245646-51-8 3-trifluoromethanesulfonyloxy-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid tert-butyl ester 
• 478837-18-2 3-exo-hydroxy-8-azabicyclo[3.2.1]octane-8carboxylic acid tert-butyl ester 
• 865106-70-3 3-Cyclopropylmethoxyimino-8-azonia-bicyclo[3.2.1]octane chloride 
• 338733-24-7 3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]octane 
• 750634-12-9 3-(3,4-Dichloro-benzyl)-8-aza-bicyclo[3.2.1]octane 
• 750634-13-0 3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 750634-11-8 3-(3,4-dichloro-benzyl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 617714-63-3 {2-[3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-methyl-ethyl}-carbamic acid tert-butyl ester 
• 617714-61-1 {2-[3-(4-chloro-benzyl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-methyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 617714-64-4 {(1S,2S)-1-[3-(4-Chloro-benzyl)-8-aza-bicyclo[3.2.1]oct-8-ylmethyl]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Retro-aza-Michael reaction in continuous flow. Approaches to synthesis of adaline and euphococcinine related products

A retro-aza-Michael ring opening reaction of tropinone and granatanone (pseudopelletierine) in flow setup was investigated and the resulting products were utilized as key intermediates in approaches to adaline and its analogues. The enantioselective flow-reaction gave products of ring opening of granatanone with enantiopurity up to 98% ee. Attempts to elaborate the retro-aza-Michael product to alkaloids are described. Lithiated carbamate derivative of tropane was converted to a tropane analogue of euphococcinine, an adaline related alkaloid (a methyl and tropane homologue of adaline 19). Reactivity of the retro-aza-Michael product under Morita-Baylis-Hillman conditions was also briefly investigated.

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Decarboxylative Oxygenation via Photoredox Catalysis

The direct conversion of aliphatic carboxylic acids to their dehomologated carbonyl analogues has been accomplished through photocatalytic decarboxylative oxygenation. This transformation is applicable to an array of carboxylic acid motifs, producing ketones, aldehydes, and amides in excellent yields. Preliminary results demonstrate that this methodology is further amenable to aldehyde substrates via in situ oxidation to the corresponding acid and subsequent decarboxylative oxygenation. We have exploited this strategy for the sequential oxidative dehomologation of linear aliphatic chains.

Tropane alkaloid compounds and method of manufacturing using sequential oxidation reactions

The present invention relates to a tropane alkaloid compound sequentially using an oxidative Mannich ring reaction and a method for producing the same. The present invention provides a tropane alkaloid compound having a structure of chemical formula 1 in

CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula (I) wherein R1 to R6, and m are as described herein, compositions including the compounds and methods of using the compounds.

Compound and application thereof

The invention provides a novel compound. The novel compound has certain inhibitory activity for indoleamine 2,3-dioxygenase (IDO) which is oxido-reductase, and accordingly the novel compound can be used for treating diseases related to the indoleamine 2,3-dioxygenase and can be applied to cancer and immunity related diseases.

Construction of 8-Azabicyclo[3.2.1]octanes via Sequential DDQ-Mediated Oxidative Mannich Reactions of N-Aryl Pyrrolidines

A concise synthesis of 8-azabicyclo[3.2.1]octanes via sequential oxidative Mannich reactions is described. This approach involves an intermolecular oxidative Mannich coupling reaction between N-aryl pyrrolidines with TMS enol ether and a subsequent intramolecular oxidative Mannich cyclization of the corresponding silyl enol ether. DDQ is used as a key oxidant for both reactions.

CDK kinase inhibitors

The present invention belongs to the technical field of medicine, and particularly relates to a CDK kinase inhibitor represented by a general formula (I), a pharmaceutically acceptable salt of the CDK kinase inhibitor, an ester of the CDK kinase inhibitor, a solvate of the CDK kinase inhibitor and stereoisomers of the CDK kinase inhibitor, the pharmaceutically acceptable salt, the ester and the solvate, wherein R1, R2, R3, R4, R5 and n are defined in the specification. The present invention further relates to preparation methods of the compounds, pharmaceutical formulations containing the compounds, pharmaceutical compositions containing the compounds, and applications of the compound, the pharmaceutically acceptable salt, the ester, the solvate and the stereoisomers in preparation of treatment and/or preparation of CDK kinase-mediated cancer associated diseases. The formula (I) is defined in the specification.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

7H-Pyrrolo[2,3-d]pyrimidine-4-thiol derivatives using as JAK-3 inhibitors

The present invention relates to a method for preparing a novel 7H-pyrrolo[2,3-d]pyrimidine-4-thiol derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient. The composition containing the novel 7H-pyrrolo[2,3-d]pyrimidine-4-thiol derivative according to the present invention can be useful for preventing or treating diseases caused by the overactivity of a Janus kinase (JAK).